ABIVAX to participate in the 15th edition of the European Large & Midcap Event in Paris

Paris, 1st October 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced its participation at the European Large & Midcap Event, to be held on October 7th and 8th, 2015 at the Palais Brongniart in Paris.

Members of ABIVAX’s senior management will be present at the Invest Securities stand to present the company’s strategy and recent events.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41